Polaryx Therapeutics, Inc.
PLYXPolaryx Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs).
Earnings
Next report
Sep 2, 2026 (in 2 months)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Polaryx Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs). The company utilizes a multi-modal approach integrating small molecule and gene therapies to address genetic and downstream pathological features of catastrophic metabolic diseases. Their therapeutic strategy focuses on activating transcription factor EB (TFEB) to enhance lysosomal biogenesis and reduce neuroinflammation.
Clinical-stage developer with multiple Orphan Drug and Fast Track designations for repurposed and novel small molecule candidates. Positioned as a potential standard-of-care provider for multiple LSD subtypes through non-invasive oral and nasal delivery systems.
Questions, answered.
- What is Polaryx Therapeutics, Inc. 's market cap?
- Polaryx Therapeutics, Inc. (PLYX) has a market capitalization of $132.6M and trades on XNAS.
- Who are Polaryx Therapeutics, Inc. 's competitors?
- Polaryx Therapeutics, Inc. 's key competitors include BioMarin Pharmaceutical Inc., Sanofi, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Polaryx Therapeutics, Inc. partner with?
- Polaryx Therapeutics, Inc. 's notable partners include Rush University Medical Center, Mstone Partners Healthcare Limited, Harmony Biosciences Holdings, Inc..
- Where is Polaryx Therapeutics, Inc. headquartered?
- Polaryx Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2026.